Emiltatug ledadotin (Emi-Le): A B7-H4-directed dolasynthen antibody-drug conjugate (ADC) being investigated in phase 1 dose expansion in patients with triple negative breast cancer who received at least one prior topoisomarase-1 inhibitor ADC.
Year: 2025
Type: article
Source: Journal of Clinical Oncology
Authors: Hyo S. Han, Kevin Kalinsky, Nour Abuhadra, Antonio Giordano, David Starks, Gerburg M. Wulf, Nicholas Patrick McAndrew, Joyce O'Shaughnessy, Alexander I. Spira, Nancy Chan, Kristen Kelley, Ritesh Parajuli, Amy M. Weise, Arvind Chaudhry, Judy S. Wang, Debra L. Richardson, Dario R. Roque, Funda Meric-Bernstam, Caroline Rogalski, Erika P. Hamilton
Institutions: Moffitt Cancer Center, Winship Cancer Institute, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Avera Health, Beth Israel Deaconess Medical Center, University of California, Los Angeles, NYU Langone Health, Huntsman Cancer Institute, University of California, Irvine, Henry Ford Hospital, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Northwestern University, The University of Texas MD Anderson Cancer Center, Mersana Therapeutics (United States), Sarah Cannon
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
Funder: Mersana Therapeutics
OpenAlex ID: W4410804840